

Thyrogen (thyrotropin alfa)Billing and Coding GuideFor Physician's Offices and Hospitals

The following is provided for informational purposes only and is not intended to substitute for the physician's independent diagnosis or treatment of each patient. Providers are responsible for the accuracy and validity of any claims, invoices, and related documentation submitted to payers. Physicians should contact the payer if they have any specific questions about coverage or payment. Any specific guidance or direction on the submission of claims offered by the payer supersedes the codes listed below. Use of the following codes does not guarantee reimbursement.





PHYSICIANS' OFFICES	Should always use the CMS 1500 Forms to make claims for Thyrogen
	(Please Refer to Sample CMS 1500 form on Page 4)
HOSPITALS	Should always use the UB-04 to make claims for Thyrogen
	(Please Refer to Sample UB 04 Form on Page 5)

BILLING MEDICAID

Coverage for Thyrogen under a state Medicaid program may be provided as either a pharmacy benefit or a medical benefit. This will vary from state to state.

Pharmacy benefit claims may be submitted electronically by an approved specialty pharmacy.

Paper claims for either pharmacy or medical benefits may be submitted using the UB-04 form or a similar billing form approved by the state Medicaid office.

Medicaid claims for Thyrogen may be submitted using the CPT-4 code or the NDC code, whichever is appropriate for the specific state program.

BILLING MEDICARE

All services and supplies, including drugs, must represent an expense to the hospital in connection with the physician's treatment of patients in an outpatient setting.

Revenue code 636 may be required by the institution's fiscal intermediary.

The following is provided for informational purposes only and is not intended to substitute for the physician's independent diagnosis or treatment of each patient. Providers are responsible for the accuracy and validity of any claims, invoices, and related documentation submitted to payers. Physicians should contact the payer if they have any specific questions about coverage or payment. Any specific guidance or direction on the submission of claims offered by the payer supersedes the codes listed below. Use of the following codes does not guarantee reimbursement.

CATEGORY	CODE	DESCRIPTION				
Revenue	250	Pharmacy, general				
Revenue	636	Drugs requiring detailed coding				
HCPCS	J3240	Thyrogen, 0.9 mg				
CPT-4	96372	Therapeutic, prophylactic or diagnostic injection (specify substance or drug); subcutaneous or intramuscular				
Service Units	1**	Thyrogen, 0.9 mg				
ICD-10	C 73	Malignant neoplasm of the thyroid gland				
NDC 58468-0030-2		Thyrogen [®] , 0.9 mg (2 vials Thyrogen)				

** EACH THYROGEN KIT CONTAINS 2 VIALS OF THYROGEN ON THE BILLING FORM, EACH VIAL SHOULD BE LISTED AS A SEPARATE LINE ITEM FOR THE DATE IT WAS ADMINISTERED



Streamlined resources from ThyrogenONE[®]

ThyrogenONE provides a single point of access



Same-day benefit verification and patient assistance

24/7 access through the online portal.

Monday through Friday 8 am - 8 pm ET

- Phone: 1-88-THYROGEN (1-888-497-6436)
 Fax: 1-888-326-1002
 Web: www.THYROGEN.com
 - Adverse reactions should be reported promptly to Sanofi Genzyme Medical Information at: 1-800-745-4447, Option 2




जिल्हान

The CMS 1500 for Physician Office

			Ť.
			CARRIER
APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12			CAL
PICA			
1. MEDICARE MEDICAID TRICARE CHAMPV	- HEALTH PLAN - BLK LUNG -	1a. INSURED'S I.D. NUMBER (F	or Program in Item 1)
(Medicare#) (Medicaid#) (ID#/DoD#) (Member IL		4. INSURED'S NAME (Last Name, First Name, Mido	B. 1.505.B
2. PATIENT'S NAME (Last Name, First Name, Middle Initial)	3. PATIENT'S BIRTH DATE SEX MM DD YY XX XX XX M F	Doe, John D	ne initial)
5. PATIENT'S ADDRESS (No., Street)	6. PATIENT RELATIONSHIP TO INSURED	7. INSURED'S ADDRESS (No., Street)	
5555 Any Street	Self Spouse Child Other		
CITY STATE	8. RESERVED FOR NUCC USE	CITY	STATE
Anytown AS ZIP CODE TELEPHONE (Include Area Code)			JII A
ZIP CODE TELEPHONE (Include Area Code) 01010 (XXX XX-XXXX		ZIP CODE TELEPHONE (In:	clude Area Code)
9. OTHER INSURED'S NAME (Last Name, First Name, Middle Initial)	10. IS PATIENT'S CONDITION RELATED TO:	11. INSURED'S POLICY GROUP OR FECA NUMBE	ER Q
			= 0
a. OTHER INSURED'S POLICY OR GROUP NUMBER	a. EMPLOYMENT? (Current or Previous)	a. INSURED'S DATE OF BIRTH	SEX
	YES NO	м_	F S
b. RESERVED FOR NUCC USE	b. AUTO ACCIDENT? PLACE (State)	b. OTHER CLAIM ID (Designated by NUCC)	SEX F
c. RESERVED FOR NUCC USE	c. OTHER ACCIDENT?	C. INSURANCE PLAN NAME OR PROGRAM NAME	L A
			I.
d. INSURANCE PLAN NAME OR PROGRAM NAME	10d. CLAIM CODES (Designated by I		PAT
PRODUCT CODE (BOX 24D)		SIS CODE (BOX 21) nt appropriate ICD-10-CM diagnos	Pa, and 9d.
- MPLETING		corresponding to patient's diagnosi	
	to myself or to the party who accepts as		
SIGNED	DATE	 primary diagnosis code. 	V
		16. DATES PATIEN UNABLE TO WORK IN CURR	
XX XX XX QUAL.	AL. MM DD YY	FROM DD YY TO	
17. NAME OF REFERRING PROVIDER OR OTHER SOURCE 17a	· • • • • • •	18. HOSPITALIZATION DATES RELATED TO CUR MM DD YY MI	RENT SERVICES
17b 19. ADDITIONAL CLAIM I VFORMATION (Designated by NUCC)	NPI	FROM TO 20. OUTSIDE LAB? \$ CHAR	050
19. ADDITIONAL CLAIM INFORMATION (Designated by NUCC)			
21. DIAGNOSIS OR NATI RE OF ILLNESS OR INJURY Relate A-L to serv	ice line below (24E) ICD nd. DIAGNO	ISIS CODE (BOX 24E)	
C73		diagnosis, from Box 21, relating to	
E.L F.L G.L		T/HCPCS code listed in Box 24D.	
I J K. L 24. A. DATE(S) OF SERVICE B. C. D. PROCE			
From To PLACE OF (Expla	DURES, SERVICES, OR SUPPLIES in Unusual Circumstances) DIAC NOSIS		J. RENDERING PROVIDER ID. #
MM DD YY NM DD YY SERVICE EMG CPT/HCP	CS MODIFIER POINTER		
01 01 16 01 01 16 J324	0 A,B,C		E UNITS (BOX 24G) unit of service. For
		exampl	e, 1 unit (Thyrogen®
² 01 01 16 01 01 16 9637	'2 A,B,C	xxx xx 1 dose is	0.9 mg, per label).
3 01 02 16 01 02 16 J 324	•		
		NPI	
4_01 02 16 01 02 16 963 7	72	NPI	Ко
*Dates are examples of administering Thyrogen on 2 consecutive			AN
		NPI	PHVSICIAN
6 PROCEDURE CODE (BOX	240)		
	NIMENITO	28. TOTAL CHARGE 29. AMOUNT PAID	30. Rsvd for NUCC Use
Document product admin		\$ \$	
31. SIGNATURE OF PHYSICIAN C NCLUDING DEOPERS OF C DEFORMED STORES OF C		33. BILLING PROVIDER INFO & PH #	,
(I certify that the statements on should consult the paver	· ·	, ,	
apply to this bill and are made a to determine which code			
administration of Thyrog	en.	a. NPI b.	
SIGNED SIGNED NUCC Instruction Manual available at: www.nucc.org	PLEASE PRINT OR TYPE	APPROVED OMB-0938-1197 FC	RM 1500 (02-12)
wooo manuchun wanaa avallable at. www.hucc.org	I LEADE I MINT ON TIFE	711 110 VED 01410-0950-1197 FC	1300 (02 12)

This sample form is intended as a reference for coding and billing for product and associated services. It is not intended to be directive; the use of the recommended codes does not guarantee reimbursement. Healthcare providers may deem other codes or policies more appropriate and should select the coding options that most accurately reflect their internal system guidelines, payer requirements, practice patterns, and the services rendered. Healthcare providers are responsible for ensuring the accuracy and validity of all billing and claims for appropriate reimbursement.

UB-04 Claim Form for O



Please visit www.Thyrogen.com for information For questions contact 1-88-THYROGEN

Outpatient Hospitals	Outpatient	Hospital	S
----------------------	------------	----------	---

iders should contact their billing/finance department.											
	3a PAT. CNTL # b. MED. REC. # 5 FED. TAX		Bill "Hos	type 1 pital ou	3X fo Itpatie	or ent"	3IOI JGł		-	4 TY OF E 13	PE SILL SX
MAIN ST	1				CA		0000)1			
CONDITION 22 2	CODES 3 24	25	26	c 27	CA 28 29	d ACDT STATE	30	/1		e	
CURRENC	E SPAN THRC	лан	36 CODE	OCC FBI	URRENCE	E SPAN	HROUG	н	17		_
Itom		Joan	CODE		0111		mood				
VALUE	CODES	4	0 CODE	VALUE COL	DES (T	ľ	41 CODE	VAL	JE CODI	ES	
											-
45 SERV. DATE	46 SE	RV. UNITS		47 TOTAL CH	ARGES		48 NO1	I-COVER	ED CHAR	3ES	49
MMDD		Х				XX					~
MMDD	YY	1		2	XXX	XX					
		Ţ									
		ut nu								_	_
		of uni ninist									
		ig = 1									
	Ì	5		·							
											_
	10	TALS									
PRIOR PAYMEN		5 EST. AM	IOUNT DU	JE	56 NPI						
					57 OTHER						
					PRV ID						
6	51 GROUP N	AME			62 INSURANCE GROUP NO.						
			65 EMP	LOYER NAM	1E						
E	F			G	_	Н		68			
72 ECI	0				-	U.		73			_
75			FIR	XUAL							
			_	ST KUAL				_			
	LAST 78 OTHER		NPI			FIR	ST XUAL	_		_	
	18 OTHER	,				FIR					
	79 OTHER	1	NPI			FIB					
		FICATION	IS ON TH	FREVERSE	APPLYT			DARE N		PART H	EREOF

Thyrogen[®] (thyrotropin alfa) for intramuscular use INDICATIONS AND USAGE

Thyrogen[®] (thyrotropin alfa) is a thyroid stimulating hormone indicated for:

Adjunctive Diagnostic Tool for Well-Differentiated Thyroid Cancer: Use as an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without radioiodine imaging in the follow-up of patients with well-differentiated thyroid cancer who have previously undergone thyroidectomy.

Limitations of Use:

- Thyrogen-stimulated Tg levels are generally lower than, and do not correlate with Tg levels after thyroid hormone withdrawal.
- Even when Thyrogen-Tg testing is performed in combination with radioiodine imaging, there remains a risk of missing a diagnosis of thyroid cancer or underestimating the extent of the disease.
- Anti-Tg Antibodies may confound the Tg assay and render Tg levels uninterpretable.

Adjunct for Thyroid Remnant Ablation in Well-Differentiated Thyroid Cancer: Use as an adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer.

Limitations of Use:

• The effect of Thyrogen on thyroid cancer recurrence greater than 5 years post-remnant ablation has not been evaluated.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

If Thyrogen is administered with radioiodine, the contraindications to radioiodine also apply to this combination regimen. Refer to the radioiodine prescribing information for a list of contraindications for radioiodine

WARNINGS AND PRECAUTIONS

Thyrogen-Induced Hyperthyroidism:

There have been reports of death in non-thyroidectomized patients and in patients with distant metastatic thyroid cancer in which events leading to death occurred within 24 hours after administration of Thyrogen. Caution should be exercised in patients who have substantial thyroid tissue still in situ or functional thyroid cancer metastases, specifically in the elderly and those with a known history of heart disease.

Hospitalization for administration of Thyrogen and post-administration observation in patients at risk should be considered.

Stroke:

There are post marketing reports of stroke in young women with risk factors for stroke, and neurological findings suggestive of stroke (e.g., unilateral weakness) occurring within 72 hours of Thyrogen administration in patients without known central nervous system metastases. The relationship between Thyrogen administration and stroke is unknown. Patients should be well-hydrated prior to treatment with Thyrogen.

Sudden Rapid Tumor Enlargement:

Sudden, rapid and painful enlargement of residual thyroid tissue or distant metastases can occur following treatment with Thyrogen. Pretreatment with glucocorticoids should be considered for patients in whom tumor expansion may compromise vital anatomic structures.

Risks Associated with Radioiodine Treatment:

If THYROGEN is administered with radioiodine (RAI), the warnings and precautions for RAI apply to this combination regimen. Refer to the RAI prescribing information for a full list of the warnings and precautions for RAI.

ADVERSE REACTIONS

The most common adverse reactions reported in clinical trials were nausea and headache.

USE IN SPECIFIC POPULATIONS

Pregnancy: If THYROGEN is administered with radioiodine, the combination regimen is contraindicated in pregnant women.

Available data with THYROGEN use in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.

Lactation: The concomitant use of THYROGEN and radioiodine (RAI) is contraindicated in lactating women. If THYROGEN is administered with RAI for diagnostic use, discontinue breastfeeding after RAI administration because of the potential for serious adverse reactions from RAI in the breastfeed infant.

If THYROGEN is not administered with RAI, the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for THYROGEN and any potential adverse effects on the breastfed child. There are no available data on the presence of thyrotropin alfa in human milk, the effects on the breastfed infant, or the effects on milk production.

Pediatric Use: Safety and effectiveness in pediatric patients have not been established.

Geriatric Use: Results from controlled trials do not indicate a difference in the safety and efficacy of Thyrogen between adult patients less than 65 years and those over 65 years of age.

Renal Impairment: Elimination of Thyrogen is significantly slower in dialysis-dependent end stage renal disease patients, resulting in prolonged elevation of TSH levels.

sanofi

Click here for full Prescribing Information